Investigation of the Efficacy of Bevacizumab Treatment in An Experimental Rat Model of Chronic Subdural Hematoma

Basit Öğe Kaydı
dc.contributor.authorSağıroğlu S.
dc.contributor.authorŞirin C.
dc.contributor.authorTurgut A.Ç.
dc.contributor.authorTomruk C.
dc.contributor.authorTuzcu A.
dc.contributor.authorErtekin E.
dc.contributor.authorUyanıkgil Y.
dc.date.accessioned2024-08-31T07:42:30Z
dc.date.available2024-08-31T07:42:30Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: Chronic subdural hematoma (cSDH), a condition that develops over time, is characterized by inflammation, angiogenesis, and membrane development. As the population's average age increases, the incidence of cSDH is expected to grow. While surgery is the primary treatment technique, medicinal therapy options are being explored for high-risk patients. Currently, the most effective therapy combination is dexamethasone (Dex) and atorvastatin (Ato); however, it is associated with an increased risk of mortality. This study explored the effects of bevacizumab (Bev), a vascular endothelial growth factor antagonist, on cSDH. Materials and Methods: Ninety-five rats were divided into four groups (n = 18): sham, control hematoma, Dex-Ato, and Bev. Two separate autologous blood injections into the subdural space were used as the model. Weight was monitored for all rats to assess changes in their overall health. The control group was given i.p. saline, the Dex-Ato treatment was given by gavage, and the Bev treatment was given i.p. On seventh, 14th and 21st days six rats from each group were sacrificed and analyzed, while 23 rats were excluded from the experiment. Results: The maximum immunological response to cSDH was observed on day 14. Hematoma volume decreased over time in all groups. Dex-Ato and Bev were both found effective, while Dex-Ato caused weight loss. Conclusion: Bev had similar effects to the Dex-Ato group and was well tolerated by rats. Given that cSDH is a disease of the elderly and vulnerable populations, Bev may be a viable alternative that can shed light on the disease's etiology for future research. © 2024 Elsevier Inc.en_US
dc.description.sponsorshipAydın Adnan Menderes Universityen_US
dc.identifier.doi10.1016/j.wneu.2024.06.036
dc.identifier.issn1878-8750
dc.identifier.pmid38871290en_US
dc.identifier.scopus2-s2.0-85198191593en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.wneu.2024.06.036
dc.identifier.urihttps://hdl.handle.net/11454/103913
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofWorld Neurosurgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectAtorvastatinen_US
dc.subjectBevacizumaben_US
dc.subjectChronic subdural hematomaen_US
dc.subjectDexamethasoneen_US
dc.subjectRat modelen_US
dc.titleInvestigation of the Efficacy of Bevacizumab Treatment in An Experimental Rat Model of Chronic Subdural Hematomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu